Axonics Modulation Technologies Inc (AXNX)vsAstraZeneca PLC (AZN)
AXNX
Axonics Modulation Technologies Inc
$0.43
-12.47%
HEALTHCARE · Cap: $3.63B
AZN
AstraZeneca PLC
$163.95
+2.97%
HEALTHCARE · Cap: $258.50B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 14108% more annual revenue ($61.37B vs $431.90M). AZN leads profitability with a 17.0% profit margin vs -1.3%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AXNX
Hold36
out of 100
Grade: F
AZN
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AXNX.
Margin of Safety
+14.6%
Fair Value
$195.23
Current Price
$163.95
$31.28 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 845.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 24.8% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
Negative free cash flow — burning cash
Currently unprofitable
Operating margin of -2.4%
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AXNX
The strongest argument for AXNX centers on Price/Book, EPS Growth, Debt/Equity. Revenue growth of 24.8% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.18 suggests the stock is reasonably priced for its growth.
Bear Case : AXNX
The primary concerns for AXNX are Free Cash Flow, Profit Margin, Operating Margin.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
AXNX profiles as a growth stock while AZN is a mature play — different risk/reward profiles.
AXNX carries more volatility with a beta of 0.83 — expect wider price swings.
AXNX is growing revenue faster at 24.8% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 36/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Axonics Modulation Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
Axonics, Inc., a medical technology company, is dedicated to the development and commercialization of sacral neuromodulation (SNM) systems. The company is headquartered in Irvine, California.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?